Neoadjuvant therapy in muscle-invasive bladder cancer: a model for rational accelerated drug development (Q38424928)

3 September 2017

1 reference

title

Neoadjuvant therapy in muscle-invasive bladder cancer: a model for rational accelerated drug development (English)

1 reference

3 September 2017

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25882563%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

author name string

Matthew I Milowsky

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25882563%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

publication date

11 March 2015

1 reference

Urologic Clinics of North America

3 September 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25882563%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

volume

42

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25882563%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25882563%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

page(s)

217-24, viii-ix

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25882563%20AND%20SRC:MED&resulttype=core&format=json

Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomised controlled trial

9 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.02.004

Survival benefit of neoadjuvant chemotherapy in non-small cell lung cancer: an updated meta-analysis of 13 randomized control trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.02.004

High-dose density neoadjuvant chemotherapy in bulky IB cervical cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.02.004

Pilot study of neoadjuvant chemotherapy with gemcitabine and oral S-1 for resectable pancreatic cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.02.004

Effect of preoperative chemotherapy on the outcome of women with operable breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.02.004

Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.02.004

Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.02.004

Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: a high-volume tertiary cancer center experience.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.02.004

Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.02.004

Adjuvant cyclophosphamide, doxorubicin, and cisplatin chemotherapy for bladder cancer: an update

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.02.004

A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.02.004

The effectiveness of off-protocol adjuvant chemotherapy for patients with urothelial carcinoma of the urinary bladder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.02.004

Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.02.004

Adjuvant chemotherapy for invasive bladder cancer: a 2013 updated systematic review and meta-analysis of randomized trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.02.004

Use of neoadjuvant chemotherapy for muscle-invasive bladder cancer is low among major European centres: results of a feasibility questionnaire

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.02.004

Contemporary use of perioperative cisplatin-based chemotherapy in patients with muscle-invasive bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.02.004

Adjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis of individual patient data Advanced Bladder Cancer (ABC) Meta-analysis Collaboration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.02.004

International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.02.004

Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.02.004

Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.02.004

Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.02.004

Neoadjuvant Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With Pegfilgrastim Support in Muscle-Invasive Urothelial Cancer: Pathologic, Radiologic, and Biomarker Correlates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.02.004

Patients with Lynch syndrome mismatch repair gene mutations are at higher risk for not only upper tract urothelial cancer but also bladder cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.02.004

Surgical factors influence bladder cancer outcomes: a cooperative group report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.02.004

Lymphadenectomy in patients with transitional cell carcinoma of the urinary bladder; significance for staging and prognosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.02.004

Age-adjusted Charlson comorbidity score is associated with treatment decisions and clinical outcomes for patients undergoing radical cystectomy for bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.02.004

Single-cell exome sequencing reveals single-nucleotide mutation characteristics of a kidney tumor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.02.004

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.02.004

Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.02.004

Molecular determinants of response to cisplatin-based neoadjuvant chemotherapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.02.004

Next generation sequencing and tumor mutation profiling: are we ready for routine use in the oncology clinic?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.02.004

Comprehensive molecular characterization of urothelial bladder carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.02.004

Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.02.004

Genome sequencing identifies a basis for everolimus sensitivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.02.004

Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.02.004

Increased frequency of ICOS+ CD4 T cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.02.004

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.02.004

Type, density, and location of immune cells within human colorectal tumors predict clinical outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.02.004

From bench to clinic and back: Perspective on the 1st IQPC Translational Research conference

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.02.004

Neoadjuvant chemotherapy use in bladder cancer: a survey of current practice and opinions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UCL.2015.02.004

10.1016/J.UCL.2015.02.004

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25882563%20AND%20SRC:MED&resulttype=core&format=json

9 June 2020

1 reference